Analysis of the Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Traumatic Brain and Spinal Cord Injury: Insight into Recent Advances in Actions of Neurochemokine Agents
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
CX3CL1 (fractalkine) is the only member of the CX3C (delta) subfamily of chemokines which is unique and combines the properties of both chemoattractant and adhesion molecules. The two-form ligand can exist either in a soluble form, like all other chemokines, and as a membrane-anchored molecule. CX3CL1 discloses its biological properties through interaction with one dedicated CX3CR1 receptor which belongs to a family of G protein-coupled receptors (GPCR). The CX3CL1/CX3CR1 axis acts in many physiological phenomena including those occurring in the central nervous system (CNS), by regulating the interactions between neurons, microglia, and immune cells. Apart from the role under physiological conditions, the CX3CL1/CX3CR1 axis was implied to have a role in different neuropathologies such as traumatic brain injury (TBI) and spinal cord injury (SCI). CNS injuries represent a serious public health problem, despite improvements in therapeutic management. To date, no effective treatment has been determined, so they constitute a leading cause of death and severe disability. The course of TBI and SCI has two consecutive poorly demarcated phases: the initial, primary injury and secondary injury. Recent evidence has implicated the role of the CX3CL1/CX3CR1 axis in neuroinflammatory processes occurring after CNS injuries. The importance of the CX3CL1/CX3CR1 axis in the pathophysiology of TBI and SCI in the context of systemic and direct local immune response is still under investigation. This paper, based on a review of the literature, updates and summarizes the current knowledge about CX3CL1/CX3CR1 axis involvement in TBI and SCI pathogenesis, indicating possible molecular and cellular mechanisms with a potential target for therapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Center for Injury Prevention and Control (U.S.). Division of Injury Response., Faul, M., Wald, M. M., Wu, L., & Coronado, V. G. (2010) · doi:10.15620/cdc.5571 · Cited by 3,494
Jung, S., Aliberti, J., Graemmel, P., Sunshine, M. J., Kreutzberg, G. W., Sher, A., & Littman, D. R. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.11.4106-4114.2000 · Cited by 2,632 · cited 1×
“leads to haploinsufficiency and the reduced superficial expression of CX3CR1 in heterozygotes which are commonly used as control groups [201].”
BackgroundKigerl, K. A., Gensel, J. C., Ankeny, D. P., Alexander, J. K., Donnelly, D. J., & Popovich, P. G. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3257-09.2009 · Cited by 2,130
Moderate and severe traumatic brain injury in adults
Maas, A. I., Stocchetti, N., & Bullock, R. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70164-9 · Cited by 2,123
A new class of membrane-bound chemokine with a CX3C motif
Bazan, J. F., Bacon, K. B., Hardiman, G., Wang, W., Soo, K., Rossi, D., Greaves, D. R., Zlotnik, A., & Schall, T. J. (1997) · Nature · doi:10.1038/385640a0 · Cited by 2,013 · cited 4×
“7 kDa, and 80 kDa after glycosylation [59, 60].”
BackgroundInfluentialThe impact of traumatic brain injuries: A global perspective
Hyder, A. A., Wunderlich, C. A., Puvanachandra, P., Gururaj, G., & Kobusingye, O. C. (2007) · Neurorehabilitation · doi:10.3233/nre-2007-22502 · Cited by 1,816 · cited 1×
“World Health Organization (WHO) claims that globally, TBI will surpass many diseases as the major cause of death and disability by the year 2020 [13].”
BackgroundControl of microglial neurotoxicity by the fractalkine receptor
Cardona, A. E., Pioro, E. P., Sasse, M. E., Kostenko, V., Cardona, S. M., Dijkstra, I. M., Huang, D., Kidd, G., Dombrowski, S., Dutta, R., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1715 · Cited by 1,531 · cited 1×
“However, in conditions like Parkinson’s disease or amyotrophic lateral sclerosis (ALS), CX3CL1 deficiency is associated with the worst outcome [206, 207].”
BackgroundAxonal pathology in traumatic brain injury
Johnson, V. E., Stewart, W., & Smith, D. H. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.01.013 · Cited by 1,273 · cited 1×
“Microscopically, the direct effects of primary injury include the immediate death of cells resulting from the direct mechanical force and secondary compression, the disruption of vascular regulation, hypoperfusion and hypoxia of injured tissues, the dysfunction of neurovascular units forming bloodbrain and blood-spina…”
BackgroundDonnelly, D. J., & Popovich, P. G. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2007.06.009 · Cited by 995
Neuroinflammation after traumatic brain injury: Opportunities for therapeutic intervention
Kumar, A., & Loane, D. J. (2012) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.06.008 · Cited by 710 · cited 2×
“Neuroinflammation is considered to be one of the leading elements of secondary injury [49].”
Background
Cited by
Microglia and aging: the role of the TREM2-DAP12 and CX3CL1-CX3CR1 axes
Mecca, C., Giambanco, I., Donato, R., & Arcuri, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010318 · Cited by 258
Shao, F., Wang, X., Wu, H., Wu, Q., & Zhang, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.825086 · Cited by 250
Yang, G., Xu, X., Gao, W., Wang, X., Zhao, Y., & Xu, Y. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1700692 · Cited by 85
Chen, X., Jiang, M., Li, H., Wang, Y., Shen, H., Li, X., Zhang, Y., Wu, J., Yu, Z., & Chen, G. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01882-6 · Cited by 85
“CX3CL1 is a unique chemokine that binds to its only receptor, CX3CR1 [24].”
Tahmasebi, F., Pasbakhsh, P., Barati, S., Madadi, S., & Kashani, I. R. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30090 · Cited by 25
“CX3CL1 is chiefly related to the expression within the gray matters and nonexpression within the white matters (e.g., the CC; Poniatowski et al., 2017).”
Background
Metadata
- Authors
- Poniatowski, Ł. A., Wojdasiewicz, P., Krawczyk, M., Szukiewicz, D., Gasik, R., Kubaszewski, Ł., & Kurkowska-Jastrzębska, I.
- Venue
- Molecular Neurobiology
- Published
- 2016-03-01
- Volume
- 54
- Issue
- 3
- Pages
- 2167-2188
- ISSN
- 0893-7648 (ISSN-L)
- 1559-1182
- OpenAlex
- W2290740392
- Cited by
- 104
- References
- 29
- FWCI
- 6.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Analysis of the Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Traumatic Brain and Spinal Cord Injury: Insight into Recent Advances in Actions of Neurochemokine Agents. https://app.cochat.ai/papers/10.1007/s12035-016-9787-4
- The paper
- Poniatowski, Ł. A., Wojdasiewicz, P., Krawczyk, M., Szukiewicz, D., Gasik, R., Kubaszewski, Ł., & Kurkowska-Jastrzębska, I. (2017). Analysis of the Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Traumatic Brain and Spinal Cord Injury: Insight into Recent Advances in Actions of Neurochemokine Agents. Molecular Neurobiology. https://doi.org/10.1007/s12035-016-9787-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.